22 results
Thumbnail

D3.344 - Biological therapy for severe chronic spontaneous urticaria associated with autoimmune atrophic gastritis

Thumbnail

D3.348 - A Case of 19p13.3 Microdeletion

Thumbnail

D3.349 - Evaluation of natural killer cells in female infertility

Thumbnail

D3.351 - Characterization of peanut roasting-enhanced Ara h 2 - Ara h 1 complexes

Thumbnail

D3.345 - Blood Dendritic Cell Antigen 3-Positive Dendritic Cells Attenuate Th2 Responses in Allergic Rhinitis and Chronic Rhinosinusitis

Thumbnail

D3.346 - Impact of local craniocerebral hypothermia on inflammatory cytokine production in ischemic stroke

Thumbnail

D3.347 - AllergoOncology: a systematic review of the impact of glycosylation on IgE antibody structure function and mechanisms of disease

Thumbnail

D3.350 - Monocytic myeloid-derived suppressor cells (M-MDSCs) increase the expression of TIGIT on γδ T cells

Thumbnail

D3.353 - An EAACI Task Force Scoping Review: Human Monocytes and Macrophages in Allergy – Implications for AllergoOncology

Thumbnail

D3.354 - Selective IgE deficiency in children: its role in autoimmunity

Thumbnail

D3.355 - Decoupling of total IgE and peripheral blood eosinophilia in pancreatic ductal adenocarcinoma: preliminary study

Thumbnail

D3.356 - Unconventional T cells in leukocyte adhesion deficiency I (LAD-I)

Thumbnail

D1.370 - Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab

Thumbnail

D1.362 - Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab

Thumbnail

D1.363 - Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis

Thumbnail

D1.364 - Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic

Thumbnail

D1.365 - ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates

Thumbnail

D1.366 - Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab

Thumbnail

D1.367 - Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results

Thumbnail

D1.368 - Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years